Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).

被引：0
|
作者：
Wong, Lilly
Jimenez Nunez, Maria Dolores
Bahlis, Nizar J.
Vangsted, Annette J.
Ramasamy, Karthik
Trudel, Suzanne
Martinez, Joaquin
Mateos, Maria-Victoria
Rodriguez Otero, Paula
Lonial, Sagar
Popat, Rakesh
Oriol, Albert
Karanes, Chatchada
Orlowski, Robert Z.
Berdeja, Jesus G.
Wang, Maria
Lamba, Manisha
Pourdehnad, Michael
Pierce, Daniel W.
Richardson, Paul G.
机构：
[1] Bristol Myers Squibb, San Diego, CA USA
[2] Celgene Res SLU, Seville, CA, Spain
[3] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[4] Rigshosp, Dept Haematol, Copenhagen, Denmark
[5] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England
[6] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[7] Univ Complutense Madrid, Hosp Octubre 12, Dept Hematol, H120 CNIO Clin Res Unit,CIBERONC, Madrid, Spain
[8] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[9] Univ Clin Navarra, Ctr Appl Med Res CIMA, IDISNA, Pamplona, Spain
[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[11] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England
[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[14] City Hope Natl Med Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA
[15] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[16] Sarah Cannon Ctr Blood Canc, Nashville, TN USA
[17] Bristol Myers Squibb, Summit, NJ USA
[18] Bristol Myers Squibb, San Francisco, CA USA
[19] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8531
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase 1 study Of CC-92480, a novel CELMoD agent, in patients with relapsed/refractory multiple myeloma: pharmacodynamic effects of dose and schedule
    Wong, Lilly
    Lamba, Manisha
    Jimenez Nunez, Maria Dolores
    Bauer, Daniel
    Bahlis, Nizar J.
    Vangsted, Annette J.
    Ramasamy, Karthik
    Trudel, Suzanne
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Rodriguez Otero, Paula
    Lonial, Sagar
    Popat, Rakesh
    Oriol, Albert
    Karanes, Chatchada
    Orlowski, Robert Z.
    Berdeja, Jesus G.
    Pourdehnad, Michael
    Pierce, Daniel W.
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 152 - 153
  • [2] Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma
    Wong, Lilly
    Lamba, Manisha
    Nunez, Maria Dolores Jimenez
    Bauer, Daniel
    Richardson, Paul G.
    Bahlis, Nizar J.
    Vangsted, Annette J.
    Ramasamy, Karthik
    Trudel, Suzanne
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Rodriguez-Otero, Paula
    Lonial, Sagar
    Popat, Rakesh
    Oriol, Albert
    Karanes, Chatchada
    Orlowski, Robert Z.
    Berdeja, Jesus G.
    Pourdehnad, Michael
    Pierce, Daniel W.
    BLOOD, 2020, 136
  • [3] First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Vangsted, Annette J.
    Ramasamy, Karthik
    Trudel, Suzanne
    Martinez, Joaquin
    Mateos, Maria-Victoria
    Rodriguez Otero, Paula
    Lonial, Sagar
    Popat, Rakesh
    Oriol, Albert
    Karanes, Chatchada
    Orlowski, Robert Z.
    Berdeja, Jesus G.
    Wong, Lilly
    Shi, Chenyang
    Lamba, Manisha
    Barnett, Evelyn
    Pierce, Daniel W.
    Pourdehnad, Michael
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] First Results From CC-92480-MM-002: A Phase 1/2 Study Of The Potent, Novel CELMoD Agent CC-92480, In Combination With Dexamethasone And Bortezomib In Patients With Relapsed/Refractory Multiple Myeloma
    Richardson, Paul G.
    Ocio, Enrique M.
    Raje, Noopur
    Gregory, Tara
    White, Darrell
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc-Steffen
    LeBlanc, Richard
    Valdes, Cesar Rodriguez
    Trudel, Suzanne
    Wasch, Ralph
    Perrot, Aurore
    Bahlis, Nizar J.
    Zhou, Zehua
    Lamba, Manisha
    Amatangelo, Michael
    Civardi, Tiziana
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Dimopoulos, Meletios A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 119 - 120
  • [5] Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
    Richardson, Paul G.
    Trudel, Suzanne
    Quach, Hang
    Popat, Rakesh
    Lonial, Sagar
    Orlowski, Robert Z.
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Spirli, Alessia
    Casas-Aviles, Ignacio
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Bahlis, Nizar J.
    BLOOD, 2022, 140 : 1366 - 1368
  • [6] CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002
    Richardson, Paul G.
    Ocio, Enrique
    Raje, Noopur S.
    Gregory, Tara
    White, Darrell
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc-Steffen
    Le Blanc, Richard
    Rodriguez, Cesar
    Trudel, Suzanne
    Waesch, Ralph
    Perrot, Aurore
    Bahlis, Nizar J.
    Zhou, Zehua
    Lamba, Manisha
    Amatangelo, Michael
    Civardi, Tiziana
    Katz, Jessica
    Aciag, Paulo M.
    Peluso, Teresa
    Dimopoulos, Meletios A.
    BLOOD, 2021, 138
  • [7] Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)
    Raab, M. -S.
    Richardson, P. G.
    Ocio, E. M.
    Raje, N.
    Gregory, T.
    White, D.
    Oriol, A.
    Sandhu, I.
    LeBlanc, R.
    Rodriguez Valdes, C.
    Trudel, S.
    Waesch, R.
    Perrot, A.
    Bahlis, N. J.
    Zhou, Z.
    Lamba, M.
    Amatangelo, M.
    Civardi, T.
    Katz, J.
    Maciag, P.
    Peluso, T.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 86 - 86
  • [8] ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study
    Shah, Jatin J.
    Zonder, Jeffrey
    Cohen, Adam
    Orlowski, Robert Z.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna
    Kaufman, Jonathan L.
    Harvey, R. Donald
    Walker, Duncan
    Litwiler, Kevin
    Karan, Sharon
    Hilder, Brandi
    Ptaszynski, Ann Marie
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 809 - 810
  • [9] Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma
    Lokhorst, Henk M.
    Plesner, Torben
    Gimsing, Peter
    Nahi, Hareth
    Minnema, Monique
    Lassen, Ulrik Niels
    Krejcik, Jakub
    Laubach, Jacob
    Lisby, Steen
    Basse, Linda
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (04) : 438 - 445
12345